CDSCO Tightens Control on IVF Consumables by Restricting Supplies to Registered Fertility Centres
The CDSCO circular is not merely an administrative instruction on the sale of IVF consumables. It is a significant regulatory intervention that strengthens the implementation of India’s Assisted Reproductive Technology (ART) regulatory framework by ensuring that critical IVF materials are supplied only to legally registered fertility centres.
The circular marks the beginning of supply-chain based enforcement, where access to essential IVF consumables becomes a regulatory checkpoint for ensuring compliance with the ART (Regulation) Act, 2021.
Background
India’s fertility treatment industry has witnessed rapid expansion over the last decade.
Growing infertility rates, delayed parenthood, increased awareness and advances in Assisted Reproductive Technology (ART) have resulted in hundreds of IVF clinics operating across the country.
To regulate this fast-growing sector, Parliament enacted:
- Assisted Reproductive Technology (Regulation) Act, 2021
- Surrogacy (Regulation) Act, 2021
The objective was to ensure:
- ethical fertility treatment
- patient safety
- quality standards
- accountability of fertility clinics
- prevention of exploitation and misuse of reproductive technologies.
Under these laws, every ART clinic and sperm bank is required to obtain registration before providing IVF and related reproductive services.
However, regulators observed that several facilities which were not registered under these Acts were still procuring IVF laboratory materials and consumables, allowing them to continue offering fertility services outside the regulatory framework.
What is the CDSCO Circular?
On 23 June 2026, the Central Drugs Standard Control Organisation (CDSCO), Medical Devices Division, issued a circular directing all stakeholders that:
- IVF media
- culture media
- reagents
- cryopreservation materials
- and related consumables used for Assisted Reproductive Technology
should be supplied only to centres registered under the Assisted Reproductive Technology (Regulation) Act, 2021 and the Surrogacy (Regulation) Act, 2021.
The circular notes that these products fall under the Medical Devices Rules, 2017 and require appropriate regulatory oversight. It further states that supplying such products to facilities other than registered centres may pose risks to patient health and facilitate misuse of ART services.
What Does the Circular Mean?
The notification changes the way compliance is enforced.
Earlier:
- Registration of ART clinics was largely monitored through inspections and licensing.
Now:
- the supply chain itself becomes a regulatory control mechanism.
If an IVF clinic is not registered,
it should not receive the essential laboratory media, reagents and consumables required to perform IVF procedures.
Effectively,
No Registration = No Supply = No IVF Procedures.
This makes compliance significantly stronger because IVF laboratories cannot function without these consumables.
Why Was This Circular Needed?
The CDSCO cites concerns that IVF media and related products were being supplied to facilities other than those registered under the ART and Surrogacy Acts. Such use could undermine patient safety and ethical reproductive healthcare.
The circular therefore seeks to:
- eliminate unauthorized fertility centres
- improve patient safety
- ensure traceability of IVF products
- strengthen ethical reproductive healthcare
- align medical device regulation with ART legislation.
Regulatory Context
This circular is part of a broader regulatory tightening by CDSCO.
Earlier in March 2026, CDSCO had already clarified that IVF-related medical devices such as:
- IUI kits
- sperm washing centrifuges
- other ART medical devices
are regulated medical devices requiring appropriate licensing under the Medical Devices Rules, 2017.
The June circular extends this regulatory approach from medical devices to IVF laboratory media, reagents and consumables, creating end-to-end oversight across the IVF ecosystem.
Impact on Stakeholders
Registered IVF Clinics
- No major operational change.
- May need to furnish proof of registration when procuring IVF consumables.
- Reinforces credibility and regulatory compliance.
Unregistered Clinics
- Will lose access to critical IVF laboratory supplies.
- May be unable to continue IVF procedures until registered under the ART Act.
- Increased risk of regulatory action if they continue operating.
Manufacturers, Importers and Distributors
The circular places direct responsibility on suppliers.
They must ensure that IVF consumables are sold only to registered ART centres and sperm banks, strengthening due diligence throughout the supply chain.
Patients
Patients stand to benefit through:
- safer fertility treatment
- treatment at legally compliant centres
- improved quality assurance
- greater transparency
- reduced risk of unethical or unregulated practices.
Why This Circular Matters
The June 2026 notification represents a shift in regulatory philosophy.
Rather than relying only on inspections of fertility clinics, regulators are now using supply-chain controls to enforce compliance.
By linking access to essential IVF consumables with statutory registration, CDSCO has effectively made regulatory compliance a prerequisite for carrying out IVF procedures.
This approach is expected to:
- improve patient safety,
- strengthen ethical reproductive practices,
- eliminate unauthorized IVF operations,
- increase accountability among suppliers, and
- reinforce the implementation of the Assisted Reproductive Technology (Regulation) Act, 2021.
Official CDSCO Notification
The notification is available on the CDSCO website:
Healthcare Events 
Leave a comment